Do analysts recommend BMGL or AIDX?

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, BMGL or AIDX?

Basel Medical Group has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $12.81M 0.06 -$580K N/A N/A 20/20 Biolabs $2.05M 1.31 -$3.74M -$0.54 N/A

Is BMGL or AIDX more profitable?

Company Net Margins Return on Equity Return on Assets Basel Medical Group N/A N/A N/A 20/20 Biolabs N/A N/A N/A

Do analysts prefer AIDX or MGRX?

20/20 Biolabs presently has a consensus price target of $5.00, suggesting a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, research analysts plainly believe 20/20 Biolabs is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer AIDX or GXAI?

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Gaxos.ai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIDX or GXAI more profitable?

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity. Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A Gaxos.ai -64.81% -38.79% -36.99%

Do analysts rate AIDX or BIAF?

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

20/20 Biolabs (AIDX) Competitors

$0.20 0.00 (-1.37%)

As of 11:56 AM Eastern

Compare

AIDX vs. BMGL, MGRX, GXAI, BIAF, and IVF

Should you buy 20/20 Biolabs stock or one of its competitors? 20/20 Biolabs's main competitors and comparable companies include Basel Medical Group (BMGL), Mangoceuticals (MGRX), Gaxos.ai (GXAI), bioAffinity Technologies (BIAF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does 20/20 Biolabs compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

In the previous week, Basel Medical Group had 11 more articles in the media than 20/20 Biolabs. MarketBeat recorded 13 mentions for Basel Medical Group and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.41 beat Basel Medical Group's score of 0.16 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
Basel Medical Group	Neutral
20/20 Biolabs	Neutral

Basel Medical Group has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$12.81M	0.06	-$580K	N/A	N/A
20/20 Biolabs	$2.05M	1.31	-$3.74M	-$0.54	N/A

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

20/20 Biolabs beats Basel Medical Group on 5 of the 8 factors compared between the two stocks.

How does 20/20 Biolabs compare to Mangoceuticals?

20/20 Biolabs (NASDAQ:AIDX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

20/20 Biolabs presently has a consensus price target of $5.00, suggesting a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, research analysts plainly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are owned by institutional investors. 27.7% of 20/20 Biolabs shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Mangoceuticals had 3 more articles in the media than 20/20 Biolabs. MarketBeat recorded 5 mentions for Mangoceuticals and 2 mentions for 20/20 Biolabs. Mangoceuticals' average media sentiment score of 0.41 beat 20/20 Biolabs' score of 0.41 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
Mangoceuticals	Neutral

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	1.31	-$3.74M	-$0.54	N/A
Mangoceuticals	$460K	7.64	-$20.64M	-$1.01	N/A

Summary

20/20 Biolabs beats Mangoceuticals on 10 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gaxos.ai?

20/20 Biolabs (NASDAQ:AIDX) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Gaxos.ai	-64.81%	-38.79%	-36.99%

In the previous week, Gaxos.ai had 4 more articles in the media than 20/20 Biolabs. MarketBeat recorded 6 mentions for Gaxos.ai and 2 mentions for 20/20 Biolabs. Gaxos.ai's average media sentiment score of 1.15 beat 20/20 Biolabs' score of 0.41 indicating that Gaxos.ai is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
Gaxos.ai	Positive

42.6% of Gaxos.ai shares are held by institutional investors. 27.7% of 20/20 Biolabs shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

20/20 Biolabs has higher revenue and earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	1.31	-$3.74M	-$0.54	N/A
Gaxos.ai	$1.93M	2.32	-$3.90M	-$0.50	N/A

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

20/20 Biolabs beats Gaxos.ai on 10 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to bioAffinity Technologies?

20/20 Biolabs (NASDAQ:AIDX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

20/20 Biolabs has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -278.90%. 20/20 Biolabs' return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
bioAffinity Technologies	-278.90%	-293.44%	-160.36%

1.6% of bioAffinity Technologies shares are owned by institutional investors. 27.7% of 20/20 Biolabs shares are owned by insiders. Comparatively, 2.4% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

20/20 Biolabs has higher earnings, but lower revenue than bioAffinity Technologies. 20/20 Biolabs is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	1.31	-$3.74M	-$0.54	N/A
bioAffinity Technologies	$6.16M	0.22	-$14.91M	-$44.27	N/A

In the previous week, bioAffinity Technologies had 4 more articles in the media than 20/20 Biolabs. MarketBeat recorded 6 mentions for bioAffinity Technologies and 2 mentions for 20/20 Biolabs. bioAffinity Technologies' average media sentiment score of 0.93 beat 20/20 Biolabs' score of 0.41 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
bioAffinity Technologies	Positive

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 2,387.56%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

20/20 Biolabs beats bioAffinity Technologies on 10 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to INVO Fertility?

20/20 Biolabs (NASDAQ:AIDX) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

20/20 Biolabs has higher earnings, but lower revenue than INVO Fertility. 20/20 Biolabs is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	1.31	-$3.74M	-$0.54	N/A
INVO Fertility	$6.84M	0.25	-$25.13M	-$135.32	N/A

20/20 Biolabs presently has a consensus price target of $5.00, suggesting a potential upside of 2,387.56%. INVO Fertility has a consensus price target of $320.00, suggesting a potential upside of 11,621.61%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts clearly believe INVO Fertility is more favorable than 20/20 Biolabs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

20/20 Biolabs has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. 20/20 Biolabs' return on equity of 0.00% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
INVO Fertility	-116.29%	-85.54%	-31.05%

In the previous week, 20/20 Biolabs and 20/20 Biolabs both had 2 articles in the media. INVO Fertility's average media sentiment score of 1.41 beat 20/20 Biolabs' score of 0.41 indicating that INVO Fertility is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
INVO Fertility	Positive

12.0% of INVO Fertility shares are held by institutional investors. 27.7% of 20/20 Biolabs shares are held by insiders. Comparatively, 0.4% of INVO Fertility shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats INVO Fertility on 8 of the 15 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIDX vs. The Competition

Export

Metric	20/20 Biolabs	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.69M	$10.79B	$7.85B	$12.00B
Dividend Yield	N/A	2.54%	2.46%	4.50%
P/E Ratio	-0.37	35.70	34.43	30.31
Price / Sales	1.31	2.16	8.84	5.84
Price / Cash	N/A	23.62	22.23	22.80
Price / Book	N/A	3.68	4.38	3.77
Net Income	-$3.74M	$335.01M	$3.51B	$390.69M
7 Day Performance	2.39%	-1.34%	-1.80%	-0.60%
1 Month Performance	-42.78%	-1.58%	-4.19%	-6.88%
1 Year Performance	N/A	19.43%	0.57%	-6.20%

20/20 Biolabs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIDX 20/20 Biolabs	2.722 of 5 stars	$0.20 -1.4%	$5.00 +2,387.6%	N/A	$2.69M	$2.05M	N/A	14	Short Interest Increase
BMGL Basel Medical Group	0.3509 of 5 stars	$5.09 +1.0%	N/A	-96.6%	$8.04M	$12.81M	N/A	82	Positive News Short Interest Increase High Trading Volume
MGRX Mangoceuticals	1.0498 of 5 stars	$0.23 -0.6%	N/A	-89.5%	$5.00M	$460K	N/A	3	News Coverage Short Interest Decrease Gap Down
GXAI Gaxos.ai	1.1579 of 5 stars	$0.44 -0.2%	N/A	-70.4%	$4.73M	$1.93M	N/A	3	News Coverage Earnings Report Gap Up
BIAF bioAffinity Technologies	0.7837 of 5 stars	$2.96 +1.5%	N/A	-92.7%	$1.78M	$5.85M	N/A	57	Negative News Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20/20 Biolabs (AIDX) Competitors

AIDX vs. BMGL, MGRX, GXAI, BIAF, and IVF

How does 20/20 Biolabs compare to Basel Medical Group?

Summary

How does 20/20 Biolabs compare to Mangoceuticals?

Summary

How does 20/20 Biolabs compare to Gaxos.ai?

Summary

How does 20/20 Biolabs compare to bioAffinity Technologies?

Summary

How does 20/20 Biolabs compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20/20 Biolabs (AIDX) Competitors

AIDX vs. BMGL, MGRX, GXAI, BIAF, and IVF

How does 20/20 Biolabs compare to Basel Medical Group?

Is BMGL or AIDX more profitable?

Does the media prefer BMGL or AIDX?

Which has stronger earnings and valuation, BMGL or AIDX?

Do analysts recommend BMGL or AIDX?

Summary

How does 20/20 Biolabs compare to Mangoceuticals?

Is AIDX or MGRX more profitable?

Do analysts prefer AIDX or MGRX?

Do institutionals & insiders hold more shares of AIDX or MGRX?

Does the media favor AIDX or MGRX?

Which has preferable earnings & valuation, AIDX or MGRX?

Summary

How does 20/20 Biolabs compare to Gaxos.ai?

Is AIDX or GXAI more profitable?

Does the media favor AIDX or GXAI?

Do institutionals and insiders have more ownership in AIDX or GXAI?

Which has better earnings & valuation, AIDX or GXAI?

Do analysts prefer AIDX or GXAI?

Summary

How does 20/20 Biolabs compare to bioAffinity Technologies?

Is AIDX or BIAF more profitable?

Do insiders & institutionals have more ownership in AIDX or BIAF?

Which has stronger earnings and valuation, AIDX or BIAF?

Does the media prefer AIDX or BIAF?

Do analysts rate AIDX or BIAF?

Summary

How does 20/20 Biolabs compare to INVO Fertility?

Which has better earnings and valuation, AIDX or IVF?

Do analysts rate AIDX or IVF?

Is AIDX or IVF more profitable?

Does the media favor AIDX or IVF?

Do institutionals & insiders believe in AIDX or IVF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools